In terms of the correlation between the phenotypes and the locations of the mutations in the SYNGAP1 gene, our patients with mutations in exons 4 and 5 displayed milder developmental delay and no comorbid epilepsy, whereas those with mutations in exons 8–15 had moderate to severe clinical manifestations (Figure 1A). Here, SYNGAP1 is linked to epilepsy.